| SOX (n = 168) | CapeOX (n = 172) |
---|---|---|
Primary site | Â | Â |
  Colon | 109 (65%) | 108 (63%) |
  Rectum | 59 (35%) | 64 (37%) |
Sex | Â | Â |
  Male | 109 (65%) | 102 (59%) |
  Female | 59 (35%) | 70 (41%) |
Age | Â | Â |
  ≤65 years | 121 (72%) | 126 (73%) |
  >65 years | 47 (28%) | 46 (27%) |
ECOG performance status | Â | Â |
  0-1 | 164 (98%) | 168 (98%) |
  2 | 4 (2%) | 4 (2%) |
Previous (neo)adjuvant therapy | Â | Â |
  Yes | 37 (22%) | 38 (22%) |
  No | 131 (78%) | 134 (78%) |
Site of metastasis | Â | Â |
  Liver metastasis | 105 (63%) | 111 (65%) |
  Non-liver metastasis | 63 (37%) | 61 (35%) |
Number of metastatic organs | Â | Â |
  One organ | 65 (39%) | 49 (29%) |
  Two organs | 61 (36%) | 70 (41%) |
  Three or more organs | 42 (25%) | 53 (31%) |
Measurability | Â | Â |
  Measurable lesions | 155 (92%) | 155 (90%) |
  Assessable lesions only | 13 (8%) | 17 (10%) |